Investment Summary

Morgan Stanley Private Equity Asia Invests In China Showyu

On January 1, 2016, private equity firm Morgan Stanley Private Equity Asia invested in healthcare services company China Showyu

Investment Highlights
  • This is Morgan Stanley Private Equity Asia’s 3rd transaction in the Healthcare Services sector.
  • This is Morgan Stanley Private Equity Asia’s 15th transaction in China.

Investment Summary

Date 2016-01-01
Target China Showyu
Sector Healthcare Services
Investor(s) Morgan Stanley Private Equity Asia
Deal Type Growth Capital

Target

China Showyu

Chengdu, China
China Showyu is a provider of aesthetic services. China Showyu was founded in 2005 and is based in Chengdu, China.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 1

DESCRIPTION

Morgan Stanley Private Equity Asia is a direct investment affiliate of Morgan Stanley that looks to acquire minority investments in companies with substantial business operations throughout Asia. The Unit has a preference for fast-growing businesses with strong brands and sustainable competitive advantages. In addition to minority deals, the Firm will also consider select control situations. Morgan Stanley Private Equity Asia was formed in 1993 and is headquartered in Hong Kong.


DEAL STATS #
Overall 21 of 36
Sector: Healthcare Services M&A 3 of 5
Type: Growth Capital M&A Deals 11 of 19
Country: China M&A 15 of 19
Year: 2016 M&A 4 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-01-01 Yongye International

Beijing, China

Yongye International is a crop nutrient company in China. Yongye's product is composed of high quality fulvic acid base and various nutrients that can supplement the absorption of fertilizer and minerals, improve crop yield, reduce chemical fertilizer/pesticide residue, and enhance natural resistance to disease. Yongye International is based in Beijing, China.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-11-18 Buchang Pharmaceutical

Heze, China

Buchang Pharmaceutical is principally engaged in R&D, production and sales of traditional Chinese medicines (”TCM”) in China with a focus on the cardiovascular diseases therapeutic area. Buchang produces branded, patented, and mostly prescription-only TCM in different delivery formats. Buchang’s products can found in 15,000 hospitals and 150,000 drug stores across China and have been used by more than 50 million patients. Buchang Pharmaceutical was founded in 1993 and is based in Heze, China.

Sell -